GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » 14-Day RSI

Innovative Pharmaceutical Biotech (HKSE:00399) 14-Day RSI : 65.25 (As of Jun. 08, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Innovative Pharmaceutical Biotech 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-06-08), Innovative Pharmaceutical Biotech's 14-Day RSI is 65.25.

The industry rank for Innovative Pharmaceutical Biotech's 14-Day RSI or its related term are showing as below:

HKSE:00399's 14-Day RSI is ranked worse than
88.73% of 2076 companies
in the Consumer Packaged Goods industry
Industry Median: 46.76 vs HKSE:00399: 65.25

Competitive Comparison of Innovative Pharmaceutical Biotech's 14-Day RSI

For the Household & Personal Products subindustry, Innovative Pharmaceutical Biotech's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovative Pharmaceutical Biotech's 14-Day RSI Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Innovative Pharmaceutical Biotech's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Innovative Pharmaceutical Biotech's 14-Day RSI falls into.



Innovative Pharmaceutical Biotech  (HKSE:00399) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovative Pharmaceutical Biotech  (HKSE:00399) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Innovative Pharmaceutical Biotech 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovative Pharmaceutical Biotech (HKSE:00399) Business Description

Traded in Other Exchanges
N/A
Address
168-200 Connaught Road Central, Unit No. 2111, 21st Floor, Sheung Wan, West Tower Shun Tak Centre, Hong Kong, HKG
Innovative Pharmaceutical Biotech Ltd is focused on developing an insulin product that could be administered orally. It has two primary segments of business: the research and development of pharmaceutical products and the trading of beauty products. It generates maximum revenue from trading in the beauty products segment.
Executives
Mao Yumin 2101 Beneficial owner
Extrawell Pharmaceutical Holdings Limited
Chau Yiu Ting 2101 Beneficial owner
Mao Yumin 2101 Beneficial owner
Chau Yiu Ting 2101 Beneficial owner

Innovative Pharmaceutical Biotech (HKSE:00399) Headlines

No Headlines